Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M260Revenue (TTM) $M23.9Net Margin (%)-229.9Altman Z-Score-1.0
Enterprise Value $M172EPS (TTM) $-2.4Operating Margin %-265.1Piotroski F-Score2
P/E(ttm)--Beneish M-Score-1.1Pre-tax Margin (%)-256.2Higher ROA y-yN
Price/Book1.810-y EBITDA Growth Rate %--Quick Ratio8.9Cash flow > EarningsN
Price/Sales10.55-y EBITDA Growth Rate %--Current Ratio9.6Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-19.1Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-32.6Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M24.8ROIC % (ttm)-113.8Gross Margin Increase y-yN

Gurus Latest Trades with ZGNX

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

ZGNX is held by these investors:



ZGNX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
HAWLEY ROGERDirector 2015-12-15Buy10,000$13.74-23.58view
HAWLEY ROGERDirector 2015-12-15Buy10,000$13.74-23.58view
TANNENBAUM RENEE PDirector 2015-12-03Buy5,000$15.4-31.82view
HAWLEY ROGERDirector 2015-06-16Buy6,250$12.72-17.45view
HAWLEY ROGERCEO 2015-03-16Buy17,500$10.480.19view
GARNER CAM LDirector 2014-06-13Buy3,750$13.28-20.93view
Shively Richard ScottChief Commercial Officer 2014-06-03Sell2,404$16.8-37.5view
RHOADS ANN DEVP, CFO, Treasurer & Sec. 2014-06-03Sell2,404$16.8-37.5view
HAWLEY ROGERCEO 2014-06-03Sell3,135$16.8-37.5view
FARR STEPHEN JPresident and COO 2014-06-03Sell2,613$16.8-37.5view

Quarterly/Annual Reports about ZGNX:

News about ZGNX:

Articles On GuruFocus.com
Analysts Weigh in on Zogenix in Light of Selling Zohydro Mar 12 2015 
Weekly CFO Buys Highlight: NGL, UNTK, ZGNX, VTSS, RVSB Dec 24 2012 
(ZGNX) CEO Roger Hawley buys 10,000 Shares Dec 06 2010 

More From Other Websites
Zogenix to Participate in the 2017 RBC Capital Markets Healthcare Conference Feb 15 2017
Zogenix Announces Initiation of Clinical Efficacy Portion of Study 1504 for ZX008 in Dravet Syndrome Feb 13 2017
Zogenix to Participate in the Leerink Partners 6th Annual Global Healthcare Conference Feb 08 2017
ZOGENIX, INC. Files SEC form 8-K, Other Events Jan 30 2017
Zogenix Announces Issuance of U.S. Patent for ZX008 in Dravet Syndrome Jan 30 2017
Blog Coverage Novartis Announced Buyback of Shares Worth $5 Billion; Considers Strategic Options for... Jan 26 2017
ZOGENIX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Jan 09 2017
Zogenix Announces CFO Transition Jan 05 2017
ZOGENIX, INC. Files SEC form 8-K, Change in Directors or Principal Officers Jan 05 2017
Zogenix Announces CFO Transition Jan 05 2017
ETFs with exposure to Zogenix, Inc. : December 21, 2016 Dec 21 2016
Is Foamix Pharmaceuticals Ltd (FOMX) Going to Burn These Hedge Funds? Dec 09 2016
ZOGENIX, INC. Files SEC form 8-K, Other Events Dec 05 2016
Zogenix Announces New Efficacy and Safety Data for ZX008 in Treatment of Seizures in Lennox Gastaut... Dec 05 2016
Hedge Funds Are Piling Back Into Zogenix, Inc. (ZGNX): Should You Follow? Dec 02 2016
Earnings Estimates Moving Higher for Zogenix (ZGNX): Time to Buy? Nov 30 2016
Moving Average Crossover Alert: Zogenix (ZGNX) Nov 23 2016
Zogenix to Participate in Oppenheimer Life Sciences Summit 2016 Nov 22 2016
ZOGENIX, INC. Financials Nov 16 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)